skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Effect of conjoint administration of tamoxifen and high-dose radiation on the development of mammary carcinoma

Journal Article · · International Journal of Radiation Oncology, Biology and Physics; (United States)
 [1];  [2];  [3]
  1. North Puget Oncology, Sedro Woolley, WA (United States)
  2. AMC Cancer Research Center, Denver, CO (United States)
  3. New York Univ., New York, NY (United States)

Tamoxifen is currently advocated for post-menopausal breast cancer patients receiving definitive irradiation after limited surgery. The purpose of this study was to assess in an experimental model for breast cancer whether the efficacy of irradiation is altered by conjoint administration of tamoxifen. To this end, rats with small tumors induced by 1-methyl-1-nitrosourea (MNU) were treated with tamoxifen, radiation, or a combination of the two modalities. Female Sprague Dawley rats were injected i.p. with 50 mg MNU/kg body weight at 50 days of age. At 64 days post carcinogen, the majority of the rats had at least one palpable mammary tumor. At that time radiation with or without tamoxifen treatment was initiated and given 5 days per week for 5 weeks. Radiation dose was 4500 cGy delivered as 25, 180 cGy fractions. Tamoxifen, 500 mg/kg body weight, was administered subcutaneously each day during the irradiation interval. The study was terminated 28 weeks after carcinogen treatment. High dose radiation alone induced a reduction in the size of existing tumors, but resulted in a significant increase in the number of tumors that were detected. Treatment with tamoxifen alone also caused a reduction in tumor volume, but had no effect on final incidence or number of mammary tumors. Combined modality treatment resulted in a significant reduction in the volume of existing tumors and suppressed the enhanced occurrence of additional tumors observed when only radiation alone was administered. The findings of this study indicate that in the context of fractionated, high dose radiation treatment of established mammary cancers, tamoxifen may reduce the likelihood of subsequent tumor development and by so doing prove a helpful simultaneous conjoint adjuvant treatment to post-operative irradiation. 35 refs., 1 fig., 2 tabs.

OSTI ID:
6700799
Journal Information:
International Journal of Radiation Oncology, Biology and Physics; (United States), Vol. 26:1; ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen
Journal Article · Mon May 01 00:00:00 EDT 1989 · Cancer (Philadelphia); (United States) · OSTI ID:6700799

Tamoxifen for breast cancer prevention
Journal Article · Wed Feb 01 00:00:00 EST 1995 · Proceedings of the Society for Experimental Biology and Medicine · OSTI ID:6700799

Flor-Essence? Herbal Tonic Promotes Mammary Tumor Development in Sprague Dawley Rats
Journal Article · Wed Jan 28 00:00:00 EST 2004 · Breast Cancer Research and Treatment · OSTI ID:6700799